Nomination Committee for Biovica for the 2023 Annual General Meeting
The Nomination Committee prior to the 2023 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2022, and the Chairman of the Board. The Nomination Committee then appoints a chairman among its members.
In accordance with the above guidelines, the Nomination Committee for the 2023 Annual General Meeting will consist of the following persons:
Anna Rylander Eklund, appointed by the Rylander family
Johan Wadell, appointed by Andra AP Fonden
Lars Holmqvist, Chairman of the Board
The members of the Nomination Committee together represent approximately 20 percent of the shares and 31 percent of the votes in the company as of December 31, 2022.
The Nomination Committee's overall responsibility is to submit proposals regarding the Chairman at the Annual General Meeting, election and remuneration of Board members, election and remuneration of the auditor, as well as principles for the appointment of the Nomination Committee and instructions for the Nomination Committee.
Shareholders who wish to submit proposals to the company's nomination committee can do so via e-mail to firstname.lastname@example.org or by letter to the address: Biovica International AB, Att: The Nomination Committee, Dag Hammarskjölds väg 54B, 752 37 Uppsala.
Biovica – Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: “Improved care for cancer patients.” Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
This cookie is installed by Google Analytics.
A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Hotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
Hotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.